Curium Announces First Commercial Doses of PYLCLARI for Patients with Prostate Cancer in Poland
PYLCLARI® provides solutions to a wider patient group across Poland where there…
Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of64Cu-PSMA-I&T for Prostate Cancer in Japan
PARIS, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Curium Group announced today that…
